Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2012

Open Access 01-05-2012 | Research Articles

Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

Authors: Kirsten Dettmar, Isabell Seitz-Merwald, Carsten Lindemann, Petra Schroeder, Diane Seimetz, Judith Atz

Published in: Clinical and Translational Oncology | Issue 5/2012

Login to get access
Metadata
Title
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo
Authors
Kirsten Dettmar
Isabell Seitz-Merwald
Carsten Lindemann
Petra Schroeder
Diane Seimetz
Judith Atz
Publication date
01-05-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0811-5

Other articles of this Issue 5/2012

Clinical and Translational Oncology 5/2012 Go to the issue

Research Articles

Episcleral brachytherapy for uveal melanoma: analysis of 136 cases

Research Articles

Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution

Research Articles

Evaluation of retroperitoneoscopic partial nephrectomy with in situ hypothermic perfusion

Educational Series

Need to implement a coordinated and multidisciplinary care in the Spanish population at increased risk for colorectal cancer

Editorial

Biomarker testing in non-small cell lung cancer: to move forward with quality

Brief Research Articles

A prospective biological study in relation to a family with Li-Fraumeni syndrome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits